TrialNeuro-oncology2026

Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas.

Yoshiki Arakawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.